Detecting predictive androgen receptor modifications in circulating prostate cancer cells

Oncotarget

Volumn 10, Issue 41, 2019, Pages 4213-4223

  Steinestel, Julie ^a,b   Luedeke, Manuel ^a   Arndt, Annette ^c   Schnoeller, Thomas J ^a   Lennerz, Jochen K ^d   Wurm, Carina ^a   Maier, Christiane ^a   Cronauer, Marcus V ^a   Steinestel, Konrad ^e   Schrader, Andres J ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c BUNDESWEHRKRANKENHAUS ULM   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Androgen receptor modification; Castration resistant prostate cancer; Circulating tumor cells; Splice variants

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; BICALUTAMIDE; CYPROTERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; HYDROXYFLUTAMIDE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN RECEPTOR V567; ANDROGEN RECEPTOR V7; ARTICLE; BIOASSAY; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DNA MODIFICATION; FEMALE; GLEASON SCORE; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; MALE; METASTASIS; MIDDLE AGED; POINT MUTATION; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; SINGLE TUBE ASSAY; VERY ELDERLY;

EID: 85068160367     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3925     Document Type: Article

References (32)

1. Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002, 52:154-179.
2. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB: Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical cancer research: an official journal of the American Association for Cancer Research 2011, 17:5913-5925.
3. Al Nakouzi N, Le Moulec S, Albiges L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C et al: Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European urology 2014.
4. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE et al: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997, 11:450-459.
5. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer research 2003, 63:149-153.
6. Chen G, Wang X, Zhang S, Lu Y, Sun Y, Zhang J, Li Z, Lu J: Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. The Prostate 2005, 63:395-406.
7. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL: Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013, 2:e00499.
8. Reid AHM, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C et al: Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate. Journal of Clinical Oncology 2010, 28:1489-1495.
9. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J et al: Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012, 2:995-1003.
10. Antonarakis ES1, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT,Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New England Journal of Medicine 2014, 371:1028-1038.
11. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL: Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007, 109:198-204.
12. Steinestel J, Schrader AJ, Luedeke M: Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med 2014, 371:2234.
13. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME: Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clinical chemistry 2010, 56:1492-1495.
14. Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, Vander Griend DJ, Szmulewitz RZ: Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. Journal of translational medicine 2014, 12:313.
15. Rabinovich SG: Measurement errors and uncertainties: theory and practice, 2nd edn. New York: AIP Press; 2000.
16. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E et al: Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer research 2012, 72:3457-3462.
17. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV. Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone. European urology 2014, 65:30-6.
18. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel J-S, Pezaro C et al: Tumor clone dynamics in lethal prostate cancer. Science Translational Medicine 2014, 6:254ra125.
19. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer research 2012, 72:2176-2182.
20. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. The Prostate 1996, 29:153-158.
21. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J: Androgen receptor gene mutations in human prostate cancer. The Journal of steroid biochemistry and molecular biology 1993, 46:759-765.
22. Chen E, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P et al: Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant
23. Androgen Receptors. Clinical cancer research: an official journal of the American Association for Cancer Research 2014.
24. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM: Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer research 2013, 73:483-489.
25. Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB: Diagnostic Challenges of Clonal Heterogeneity in Prostate Cancer. Journal of Clinical Oncology 2014:JCO. 2013.2050. 3540.
26. Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P: Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer research 2014, 74:2270-2282.
27. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al: Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010, 120:2715-2730.
28. Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O: Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer research 2005, 65:9611-9616.
29. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT: Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:6201-6206.
30. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 1997, 3:1383-1388.
31. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG et al: An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide). Cancer Discovery 2013, 3:1030-1043.
32. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT: Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. The Journal of biological chemistry 2007, 282:13648-13655.